ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Arbutus Biopharma Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborations and licenses | $12.60M | $3.92M | $14.27M | $31.37M | $4.88M | $3.52M | $4.36M | $5.95M | – | 89.5% | +221.5% |
| Non-cash royalty revenue | $1.48M | $2.25M | $3.87M | $7.65M | $6.11M | $3.40M | $1.66M | – | – | 10.5% | -34.2% |
| Royalty | – | – | – | – | $200.00K | $200.00K | $300.00K | $154.00K | $191.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Arbutus Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.